WAYPOINT: 对于鼻多重症患者来说,我们已经到达了吗?
Jack L Birkenbeuel1, Vinay K Rathi1
1Department of Otolaryngology, Head & Neck Surgery, The Ohio State University College of Medicine, Columbus, OH, USA.
Med (New York, N.Y.)
|June 14, 2025
概括
在患有鼻多重症的慢性鼻炎的患者中,Tezepelumab显著降低了症状和客观测量. 在52周的治疗后,WAYPOINT试验显示了疾病负担的有意义改善.
科学领域:
- 呼吸系统医学 呼吸系统医学
- 免疫学 免疫学 免疫学
- 临床试验 临床试验
背景情况:
- 长期鼻综合性鼻炎 (CRSwNP) 具有显著的疾病负担.
- 目前的治疗方法对某些患者的疗效有限.
研究的目的:
- 评估tzepelumab在治疗CRSwNP中的疗效.
- 评估tzepelumab对CRSwNP客观和主观测量的影响.
主要方法:
- 这项研究涉及WAYPOINT试验,比较tezepelumab与安慰剂.
- 结果在52周后进行了测量,包括鼻息肉得分,救援药物/手术率以及患者报告的症状.
主要成果:
- 与安慰剂相比,Tezepelumab在鼻多得分上显示了统计学上显著和临床上有意义的减少.
- 包括鼻塞和嗅觉丧失在内的主观测量也显示出显著的改善.
- 在tzepelumab组中,救援类固醇使用和手术的发生率降低了.
结论:
- 佩鲁马布是一种有效的治疗选择,可以减少CRSwNP的疾病负担.
- 药物对条件的客观和主观方面都有显著的好处.
相关概念视频
Epistaxis
141
Epistaxis, or nosebleeds, occurs when small, swollen blood vessels in the nasal mucous membrane rupture. Typically, the anterior septum is the primary site of occurrence.
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
141
Cystic Fibrosis: Management
148
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
148
Peptic Ulcer Disease IV: Management
78
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
78
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
162
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
162
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
149
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
149
Suctioning the Nasopharyngeal Airway
316
Nasopharyngeal suctioning is a procedure to remove secretions from the upper part of the respiratory tract that the patient cannot clear independently. It helps maintain airway patency and prevents complications such as aspiration pneumonia.
Equipment Required
Equipment Required
316


